Among these NAEs, exenatide accounted for 10,175 cases (35.14%), liraglutide for 3,686 cases (12.73%), lixisenatide for 256 cases (0.88%), dulaglutide for 6,034 cases (20.84%), semaglutide for 5,935 cases (20.50%), and tirzepatide for 2,867 cases (9.90%)
Activating these receptors improves how your body handles blood sugar, reduces inflammation in your gut lining, and may even protect heart function
Diabetes Care 39 , 214221 (2016)
Glucagon receptor activation Here is where things get complicated for microdosing advocates
Fatigue should be discussed with a doctor when it is persistent, severe, or associated with dizziness, weakness, fainting, low blood sugar symptoms, inability to exercise, difficulty eating enough, or rapid decline in function
If youre currently using GLP-1 weight loss medications , share your experience in the comments below